Dual: Multi-pronged attack

Dual developing PP2A activators to disrupt multiple cancer-associated pathways

Dual Therapeutics LLC is developing first-in-class oral small molecules that directly activate protein phosphatase 2 to disrupt multiple cancer pathways simultaneously. By restoring the phosphatase's activity to normal levels, the approach could treat prostate cancers that are resistant to anti-androgens and chemotherapy.

Protein phosphatase 2 (PPP2CA; PP2A) is a serine/threonine phosphatase that is a tumor suppressor. It is down-regulated in various cancers.

D. Amy Trainor, a venture

Read the full 653 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE